| Title: |
Our Extracorporeal Membrane Oxygenation (ECMO) Experiences in the COVID-19 Pandemic and Intensive Care Unit. |
| Authors: |
Vatansever, Şule; Uluç, Kamuran; Çolakoğlu, Şükran Merve; Küçük, Rabia Sarı; Şensöz, Gaye; Turgut, Namigar |
| Source: |
Turkish Journal of Intensive Care; 2023Suppl1, Vol. 21, p117-117, 1p |
| Subject Terms: |
Extracorporeal membrane oxygenation; Intensive care units; COVID-19 pandemic; Adult respiratory distress syndrome; COVID-19; COVID-19 treatment |
| Abstract: |
Introduction: The need for mechanical ventilation and mortality rates are high as a result of acute respiratory distress syndrome (ARDS) developing after COVID-19. The role of Extracorporeal Membrane Oxygenation (ECMO) supportive therapy in the COVID-19 pandemic is still unclear. In our study, we aimed to share the effectiveness of the ECMO supportive treatment, the difficulties we encountered, and our clinical experiences in 26 patients with ARDS caused by COVID-19 pneumonia in the intensive care unit of a third-level training and research hospital during the pandemic period. Materials and Methods: Patients who received ECMO support between 11.03.2020 and 01.03.2021 in the University of Health Sciences Turkey, Prof. Dr. Cemil Taşcıoğlu City Hospital were evaluated retrospectively. During the study period, ECMO supportive treatment was applied to 26 patients due to ARDS. Results: A total of 26 patients underwent V-V ECMO and 2 patients could be decannulated. Sixteen (61.5%) of the patients were male, 10 (38.5%) were female, with a mean age of 51.3 (29-71). Mean time from hospitalization to intubation was 10.1±5.9 (1-27) days, mean duration of stay on mechanical ventilator before ECMO was 9.7±7.2 (1-28) days, mean duration of stay on ECMO support was 12. It was found to be 3 (1-23) days (Table 1). Of the 26 patients who received ECMO support, 24 died. One of the surviving patients left ECMO support after 13 days and the other 16 days later. After ECMO, MV support continued for 21 days and 16 days, respectively. Surviving patients were discharged with full recovery. ECMO was terminated due to bleeding in two patients and cannula removal in two patients. Conclusion: ECMO supportive therapy is associated with high mortality in ARDS patients developing after COVID-19. However, in COVID 19 disease, ECMO is a life-saving support method when applied in the early period. The usefulness of ECMO as a rescue therapy in critically ill patients with ARDS due to COVID-19 has so far been limited and more studies are needed for its application in these patients. [ABSTRACT FROM AUTHOR] |
| : |
Copyright of Turkish Journal of Intensive Care is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |